| Literature DB >> 23684876 |
O M Doyle1, J Ashburner2, F O Zelaya3, S C R Williams4, M A Mehta5, A F Marquand6.
Abstract
Neuroimaging data are increasingly being used to predict potential outcomes or groupings, such as clinical severity, drug dose response, and transitional illness states. In these examples, the variable (target) we want to predict is ordinal in nature. Conventional classification schemes assume that the targets are nominal and hence ignore their ranked nature, whereas parametric and/or non-parametric regression models enforce a metric notion of distance between classes. Here, we propose a novel, alternative multivariate approach that overcomes these limitations - whole brain probabilistic ordinal regression using a Gaussian process framework. We applied this technique to two data sets of pharmacological neuroimaging data from healthy volunteers. The first study was designed to investigate the effect of ketamine on brain activity and its subsequent modulation with two compounds - lamotrigine and risperidone. The second study investigates the effect of scopolamine on cerebral blood flow and its modulation using donepezil. We compared ordinal regression to multi-class classification schemes and metric regression. Considering the modulation of ketamine with lamotrigine, we found that ordinal regression significantly outperformed multi-class classification and metric regression in terms of accuracy and mean absolute error. However, for risperidone ordinal regression significantly outperformed metric regression but performed similarly to multi-class classification both in terms of accuracy and mean absolute error. For the scopolamine data set, ordinal regression was found to outperform both multi-class and metric regression techniques considering the regional cerebral blood flow in the anterior cingulate cortex. Ordinal regression was thus the only method that performed well in all cases. Our results indicate the potential of an ordinal regression approach for neuroimaging data while providing a fully probabilistic framework with elegant approaches for model selection.Entities:
Keywords: Gaussian processes; Ketamine; Multivariate; Ordinal regression; Pharmacological MRI; Scopolamine
Mesh:
Year: 2013 PMID: 23684876 PMCID: PMC4068378 DOI: 10.1016/j.neuroimage.2013.05.036
Source DB: PubMed Journal: Neuroimage ISSN: 1053-8119 Impact factor: 6.556
Fig. 1Ordinal regression likelihood functions for a problem with three ordinal classes (R = 3) and hence two threshold variables with b1 = − 6 and b2 = 6 and two extremity threshold constants b0 and b3 which are set to − ∞ and + ∞, respectively. The case for the noise parameter σ = 1 appears in boldfaced blue and two additional greyed out functions are displayed for σ = 0.01 (approximating the noise-free case) and σ = 2.
Probabilistic code words for each class. C1 — class 1, C2 — class 2 and C3 — class 3. ‘0’ implies that the output from the binary classifier is expected to be the first class listed. Similarly, ‘1’ implies the second class listed. ‘0.5’ implies that the classifier is neutral, for example testing an instance from class 3 on the classifier trained on class 1 and class 2.
| Binary classifier pairs | |||
|---|---|---|---|
| C1 × C2 | C1 × C3 | C2 × C3 | |
| C1 | 0 | 0 | 0.5 |
| C2 | 1 | 0.5 | 0 |
| C3 | 0.5 | 1 | 1 |
Fig. 2Confusion matrices using both lamotrigine (LAM) and risperidone (RIS) as the intermediate class for ORGP, PMCGP, MCGP and RR. The greyscale which is provided for visualisation with bright colouring in the diagonal and dark colouring off-diagonal indicates good performance. (a) Visualisation of the ideal confusion, (b) placebo–lamotrigine–ketamine for ORGP, (c) placebo–lamotrigine–ketamine for PMCGP, (d) placebo–lamotrigine–ketamine for RR, (e) placebo–risperidone–ketamine for ORGP, (f) placebo–risperidone–ketamine for PMCGP, (g) placebo–risperidone–ketamine for MCGP and (h) placebo–risperidone–ketamine for RR.
Performance metrics for ordinal regression (ORGP) and pairwise multi-class classification (MCGP), multi-class classification (MCGP) and ridge regression (RR). Model evidence is quantified using the negative marginal log likelihood computed using the entire data set. LAM: lamotrigine, RIS: risperidone, MAE: mean absolute error, AIC: Akaike information criterion, and BIC: Bayesian information criterion.
| Performance metric | LAM (ORGP) | LAM (PMCGP) | LAM (MCGP) | LAM (RR) | RIS (ORGP) | RIS (PMCGP) | RIS (MCGP) | RIS (RR) |
|---|---|---|---|---|---|---|---|---|
| Accuracy | 72.9% | 60.4% | 56.3% | 70.8% | 60.4% | 56.3% | 56.3% | 50.0% |
| MAE | 0.29 | 0.46 | 0.52 | 0.40 | 0.44 | 0.50 | 0.50 | 0.61 |
| Kendall's tau | 0.70 | 0.61 | 0.53 | 0.71 | 0.57 | 0.61 | 0.61 | 0.46 |
| Model evidence | 39.0 | – | 44.6 | – | 40.4 | 45.6 | ||
| AIC | 86.9 | – | 93.5 | – | 89.7 | 95.5 | ||
| BIC | 93.5 | – | 96.9 | – | 96.3 | 98.9 |
Accuracy > chance (33%) p < 0.05.
ORGP outperforms PMCGP p < 0.05.
ORGP outperforms MCGP p < 0.05.
ORGP outperforms RR p < 0.05.
Fig. 3Multivariate maps extracted from both ORGP and MCGP. For ORGP, a single weight map is produced whereas, for MCGP a weight map can be computed per class. Only weight maps with significant classification accuracy were computed. For visualisation, each map is scaled so that its maximum (absolute) intensity is 1. ORGP:PLK — ordinal regression weight vector for all three classes. ORGP:PRK — ordinal regression weight vector for all three classes considering risperidone as the intermediate class. MCGP:PLALAM — multi-class classification weight vector for the placebo class considering lamotrigine as the intermediate class. MCGP:KETLAM — multi-class classification weight vector for the ketamine class considering lamotrigine as the intermediate class. MCGP:PLARIS — multi-class classification weight vector for the placebo class considering risperidone as the intermediate class. MCGP:KETRIS — multi-class classification weight vector for the ketamine class considering risperidone as the intermediate class.
Performance metrics for ordinal regression (ORGP) and pairwise multi-class classification (MCGP), multi-class classification (MCGP) and ridge regression (RR). Model evidence is quantified using the negative marginal log likelihood computed using the entire data set. MAE — mean absolute error, AIC: Akaike information criterion, BIC: Bayesian information criterion, and DON: donepezil.
| Performance Metric | DON (ORGP) | DON (PMCGP) | DON (MCGP) | DON (RR) | |
|---|---|---|---|---|---|
| Anterior cingulate | Accuracy | 73.3% | 40.0% | 51.1% | 42.4% |
| MAE | 0.29 | 0.73 | 0.51 | 0.69 | |
| Kendall's tau | 0.70 | 0.21 | 0.53 | 0.32 | |
| Model evidence | 24.8 | – | 38.8 | – | |
| AIC | 58.6 | – | 86.6 | – | |
| BIC | 64.8 | – | 92.8 | – | |
| Occipital lobe | Accuracy | 64.4% | 64.4% | 60.0% | 64.4% |
| MAE | 0.378 | 0.40 | 0.46 | 0.38 | |
| Kendall's tau | 0.63 | 0.59 | 0.52 | 0.60 | |
| Model evidence | 27.7 | – | 35.9 | – | |
| AIC | 64.4 | – | 80.8 | – | |
| BIC | 70.6 | – | 87.0 | – | |
| Thalamus | Accuracy | 80.0% | 60.0% | 68.9% | 66.7% |
| MAE | 0.20 | 0.42 | 0.31 | 0.36 | |
| Kendall's tau | 0.81 | 0.60 | 0.72 | 0.66 | |
| Model evidence | 20.8 | – | 29.8 | – | |
| AIC | 50.6 | – | 68.6 | – | |
| BIC | 56.8 | – | 74.8 | – |
Accuracy > chance (33%) p < 0.05.
ORGP outperforms PMCGP p < 0.05.
ORGP outperforms MCGP p < 0.05.
ORGP outperforms RR p < 0.05.